

CLINICAL UPDATE

Brand Name	Not Available
Generic Name	mupirocin/lidocaine
Drug Manufacturer	Sincerus Florida, LLC

Clinical Update

TYPE OF CLINICAL UPDATE

New Formulation

FDA APPROVAL DATE

Not available

LAUNCH DATE

May 15, 2019

REVIEW DESIGNATION

Not available

TYPE OF REVIEW

Not available

DISPENSING RESTRICTIONS

Not available

Overview

INDICATION(S) FOR USE

Mupirocin: It is Indicated for the treatment of impetigo and secondary skin infections, leading to traumatic skin lesions, due to *Staphylococcus aureus* and *Streptococcus pyogenes*.

Lidocaine: Topical anesthetic for localized pain.

MECHANISMS OF ACTION

Mupirocin: Primarily works by inhibiting bacterial protein synthesis. Due to its unique mode of action of inhibiting the activity of bacterial isoleucyl-tRNA synthetase, mupirocin does not demonstrate cross-resistance with other classes of antimicrobial agents, giving it a therapeutic advantage.

Lidocaine: Blocks both the initiation and conduction of nerve impulses by decreasing the neuronal membrane's permeability to sodium ions, which results in inhibition of depolarization with resultant blockade of conduction.

DOSAGE FORM(S) AND STRENGTH(S)

Ointment: Mupirocin 2%/Lidocaine 2%; 30 g in 1 bottle, pump

DOSE & ADMINISTRATION

Mupirocin:

This document is designed to be an informational resource to facilitate discussion and should be used neither as a basis for clinical decision-making or treatment nor as a substitute for reading original literature. RxAdvance makes every effort to ensure that the information provided is up-to-date, accurate, and complete, but no guarantee is made to that effect. If this information is provided to clients or vendors, it is subject to any contractual confidentiality provisions. Third-party disclosures are in violation of confidentiality provisions.

CLINICAL UPDATE

- *Staphylococcus aureus* decolonization: 500 mg (an amount sufficient to cover the top of a cotton swab) can be applied into each nostril.
- Superficial skin infections (on- and off-label): Apply to affected area 2-3 times daily. Length of treatment is dependent on infection.

Lidocaine: Maximum – 20 g of ointment/day

EFFICACY

Not available

This document is designed to be an informational resource to facilitate discussion and should be used neither as a basis for clinical decision-making or treatment nor as a substitute for reading original literature. RxAdvance makes every effort to ensure that the information provided is up-to-date, accurate, and complete, but no guarantee is made to that effect. If this information is provided to clients or vendors, it is subject to any contractual confidentiality provisions. Third-party disclosures are in violation of confidentiality provisions.